人乳头瘤病毒(HPV)筛查结合阴道自取样普遍可及:一项实施性试验的结果
该实施性试验在17家初级保健机构纳入3121名应接受宫颈筛查者,提供临床医生取样或阴道自取样(诊所或家中)选择。95%选择阴道自取样,12.9%检出HPV,95%检出者返回进一步检查;非16/18型HPV的细胞学分流完成率为92%,但存在民族和筛查史差异。
要点
- 阴道自取样接受度高,95%(2954/3121)参与者选择自取样。
- HPV检出率为12.9%(404/3121),其中HPV 16/18型占2.6%(82/3121)。
- 95%(384/404)HPV阳性者返回接受细胞学或阴道镜检查。
核心结论
- 本研究证实了提供阴道自取样普遍选择的宫颈筛查可行,并显示对阴道自取样的明显偏好。
- 在细胞学分流的公平提供方面仍存在挑战,持续的项目监测至关重要。
研究设计与样本
- 实施性试验,在17家初级保健机构进行。
- 纳入3121名应接受宫颈筛查者,可选择临床医生取样的宫颈检测或阴道自取样(诊所或家中),除非临床需要宫颈联合检测(HPV和细胞学)。
主要发现
- 95%(2954/3121,95%CI [93.8, 95.4])的参与者进行了阴道自取样。
- 12.9%(404/3121,95%CI [11.8, 14.2])的参与者检出HPV。
- 95%(384/404,95%CI [92.5, 97.0])的HPV检出者进行了随访细胞学或阴道镜检查。
- 2.6%(82/3121,95%CI [2.1, 3.2])检出HPV 16/18型,全部接受了阴道镜检查。
- 阴道自取样检出非16/18型HPV(HPV其他)者中,92%(276/301,95%CI [88.0, 94.3])完成了细胞学分流,且因民族和筛查史而异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Determine the feasibility of high-risk human papillomavirus (HPV)-based cervical screening that included the option of a vaginal swab HPV test (vaginal self-test). DESIGN: Implementation trial. SETTING: 17 primary care practices. POPULATION OR SAMPLE: People due for a cervical screening test. METHODS: Participants could choose a clinician-taken cervical test or a vaginal self-test (undertaken in clinic or at home), unless a cervical co-test (HPV and cytology) was clinically indicated. MAIN OUTCOME MEASURES: Proportion of participants who had (a) a vaginal self-test, (b) an HPV-detected result and (c) HPV detected on a vaginal self-test and returned for further investigation. RESULTS: 3121 people were enrolled. Participation rates were high for people of all recorded ethnicities. A vaginal self-test was undertaken by 95% (2954/3121, 95% confidence interval [CI] [93.8, 95.4]) of people. HPV was detected in 12.9% (404/3121, 95% CI [11.8, 14.2]) of people. 95% (384/404, 95% CI [92.5, 97.0]) of people with HPV detected had follow-up cytology or colposcopy. 2.6% (82/3121, 95% CI [2.1, 3.2]) had HPV 16/18 detected, all of whom attended colposcopy. Cytology triage was completed for 92% (276/301, 95% CI [88.0, 94.3]) of people with non-16/18 HPV types (HPV other) detected on a vaginal self-test. This varied by ethnicity and screening history. CONCLUSION: This study confirms the feasibility of cervical screening with the universal option of a vaginal self-test and demonstrated a clear preference for the vaginal self-test. Challenges remain in relation to equitable provision of cytology triage. Ongoing programme monitoring is imperative. TRIAL REGISTRATION: Australia and New Zealand Clinical Trial Register. ANZCTR Reference number: ACTRN12622000699763 (https://anzctr.org.au/).
引用
- Sykes P, Innes C, Bell R, et al. Human Papillomavirus (HPV) Screening With Universal Access to Vaginal Self-Testing: Outcomes of an Implementation Trial. BJOG. 2025. PMID: 40162498. doi:10.1111/1471-0528.18159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。